Security key
114082308
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA)
CUSIP: 114082308
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.005 per share
- Total 13F shares
- 3,574,358
- Total 13F value
- $711,400
- Share change
- +3,035,631
- SEC-reported price per share
- $0.20
- Number of holders
- 19
- Value change
- +$590,836
- Number of buys
- 11
- Number of sells
- 4
- Shares outstanding
- 1,216,283
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
19
Top holders
10
ERNA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Ernexa Therapeutics Inc. SEC filings
Ernexa Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 114082308
Recent filing periods:
Ownership snapshot
Top reported holders of ERNA - Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Charles Cherington
Disclosed value leader
Charles Cherington
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 35%
13D/G row: Charles Cherington
Showing 1-6 of 15 holder rows.
Quick read
Charles Cherington leads the comparable SEC ownership view at 35%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Charles Cherington's linked filing trail.
Comparable ownership
Top 5
Charles Cherington
35%
Freebird Partners LP
9.9%
Shameek Konar
9.7%
Bleichroeder LP
6.9%
John D. Halpern
5.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Charles Cherington |
13D/G
3/4/5
10%+ Owner
|
35%
|
$12,949,602
10,791,335 shares
|
$0 | 10 Feb 2026 |
| Freebird Partners LP |
3/4/5
13D/G
10%+ Owner
|
9.9%
from 13D/G
|
$1,503,337
2,774,627 shares
mixed-class rows
|
— | 14 Dec 2023 |
| Shameek Konar |
13D/G
|
9.7%
|
$21,302
118,342 shares
|
-$597,053 | 10 Feb 2026 |
| Bleichroeder LP |
13D/G
|
6.9%
|
$14,400
80,000 shares
|
$0 | 31 Mar 2026 |
| John D. Halpern |
3/4/5
13D/G
10%+ Owner
|
5.6%
from 13D/G
|
$1,118,891
1,123,006 shares
mixed-class rows
|
— | 02 Dec 2022 |
| Nicholas J. Singer |
3/4/5
13D/G
Director · Nicholas Jason Singer
|
4.9%
from 13D/G
|
$962,330
954,608 shares
mixed-class rows
|
— | 02 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
19
Shares
3,574,358
Rows available
19
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
14
Q1 2026 holders
19
Holder diff
5
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend